GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » YoY EBITDA Growth

CLDI (Calidi Biotherapeutics) YoY EBITDA Growth : 92.01% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Calidi Biotherapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 92.01%.

Calidi Biotherapeutics's EBITDA per Share for the three months ended in Dec. 2024 was $-0.17.

Calidi Biotherapeutics YoY EBITDA Growth Historical Data

The historical data trend for Calidi Biotherapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics YoY EBITDA Growth Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
- -32.71 -146.22 -128.92 84.54

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.99 -9.96 -190.92 39.40 92.01

Calidi Biotherapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Calidi Biotherapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-2.464--15.94)/ | -15.94 |
=84.54 %

Calidi Biotherapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(-0.172--2.153)/ | -2.153 |
=92.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » YoY EBITDA Growth
Comparable Companies
INAB AFMD ABVC PHGE BIVI EQ MBRX BOLT ZEOX SABS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.calidibio.com
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.